- Home
- OCUP vs ONDS Comparison
OCUP vs ONDS Comparison
Compare OCUP & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUP
- ONDS
- Stock Information
- Founded
- OCUP 2018
- ONDS N/A
- Country
- OCUP United States
- ONDS United States
- Employees
- OCUP N/A
- ONDS N/A
- Industry
- OCUP Biotechnology: Pharmaceutical Preparations
- ONDS Telecommunications Equipment
- Sector
- OCUP Health Care
- ONDS Telecommunications
- Exchange
- OCUP Nasdaq
- ONDS Nasdaq
- Market Cap
- OCUP 53.1M
- ONDS 52.7M
- IPO Year
- OCUP N/A
- ONDS N/A
- Fundamental
- Price
- OCUP $1.25
- ONDS $0.99
- Analyst Decision
- OCUP Strong Buy
- ONDS Strong Buy
- Analyst Count
- OCUP 3
- ONDS 2
- Target Price
- OCUP $18.67
- ONDS $2.50
- AVG Volume (30 Days)
- OCUP 96.2K
- ONDS 413.3K
- Earning Date
- OCUP 11-11-2024
- ONDS 11-12-2024
- Dividend Yield
- OCUP N/A
- ONDS N/A
- EPS Growth
- OCUP N/A
- ONDS N/A
- EPS
- OCUP N/A
- ONDS N/A
- Revenue
- OCUP $16,449,000.00
- ONDS $9,209,335.00
- Revenue This Year
- OCUP N/A
- ONDS N/A
- Revenue Next Year
- OCUP $258.69
- ONDS $217.16
- P/E Ratio
- OCUP N/A
- ONDS N/A
- Revenue Growth
- OCUP N/A
- ONDS 0.36
- 52 Week Low
- OCUP $1.15
- ONDS $0.32
- 52 Week High
- OCUP $3.40
- ONDS $1.99
- Technical
- Relative Strength Index (RSI)
- OCUP 41.90
- ONDS 64.81
- Support Level
- OCUP $1.24
- ONDS $0.85
- Resistance Level
- OCUP $1.39
- ONDS $1.02
- Average True Range (ATR)
- OCUP 0.07
- ONDS 0.08
- MACD
- OCUP -0.00
- ONDS 0.03
- Stochastic Oscillator
- OCUP 11.11
- ONDS 85.56
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.